Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab + apatinib + FOLFOX4 for unresectable advanced cholangiocarcinoma
ChiCTR2100048021Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jul 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib, fluorouracil, folinic acid and oxaliplatin in cholangiocarcinoma (CCA), extrahepatic cholangiocarcinoma (eCCA), intrahepatic cholangiocarcinoma (ICC) and 3 more, sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibfluorouracilfolinic acidoxaliplatin
03
Conditions
cholangiocarcinoma (CCA)extrahepatic cholangiocarcinoma (eCCA)intrahepatic cholangiocarcinoma (ICC)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on ChiCTR2100048021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048021.